A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Clinical trial NCT05033080 · COMPLETED
Trial details
- NCT number
- NCT05033080
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-14
- Primary completion
- 2023-05-12
- Enrollment
- 435
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.